Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
pharmaphorum20h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
MedPage Today on MSN13h
Gene Therapy Promising for Rare Genetic Cardiomyopathy
CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...
The Lancet8h
Vedolizumab prophylaxis against postoperative Crohn's disease recurrence
Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...
GlobalData on MSN22h
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...
Taiwan News1h
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In ...